Gastrin-releasing peptide (GRP), the 27 amino acid mammalian form of bombesin, was studied in human inferior turbinate nasal mucosa. The GRP content of the mucosa measured by radioimmunoassay was 0.60±0.25 pmol/g tissue (n = 9 patients; mean±SEM). GRP-immunoreactive nerves detected by the immunogold method of indirect immunohistochemistry were found predominantly in small muscular arteries, arterioles, venous sinusoids, and between submucosal gland acini.
Introduction
Gastrin-releasing peptide (GRP)' is a 27 amino acid (2,859 g/mol) mammalian peptide (1, 2) that shares sequence homology with bombesin (3), a 14 amino acid amphibian peptide. The common carboxy-terminal sequence is essential for receptor recognition and biological activity. Other GRP-related peptides include GRP [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] (GRP [10] ; neuromedin C), and GRP [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] (GRP [14] ; references 3 and 4) . GRP is located in nerve fibers (1) and pulmonary neuroendocrine cells (1) , and can be detected in plasma (5, 6) . GRP acts as a neurotransmitter (7, 8) , a neuroregulatory hormone (1, 9) , and a growth factor in fetal (10) , normal (11) , and neoplastic (12, 13) respiratory tissues (1) . Recently, it has been demonstrated that GRP significantly stimulates mucus secretion from cat trachea maintained in explant cultures (14) . GRP is also a stimulant of pancreatic exocrine secretion (15, 16) and a participant in the central and vagal control of gastric mucosal homeostasis (17) (18) (19) . Therefore, GRP is an exceedingly interesting peptide which may have many relevant effects on respiratory tissues.
To investigate the potential roles ofGRP in human respiratory mucosal function, human inferior nasal mucosa was analyzed for GRP content by RIA, for the presence of GRP-immunoreactive nerves and other GRP-containing structures by indirect immunohistochemistry, and for the presence of GRP binding sites by autoradiography. The secretogogue activity of GRP was assessed by culturing human nasal mucosal fragments with GRP and measuring the secretion of lactoferrin, a product of submucosal gland serous cells (20) , and acid-precipitable, [3H]glucosamine-labeled respiratory glycoconjugates (21, 22) .
Methods
Tissue handling. Human inferior turbinate tissue was obtained from 14 patients with nasal obstruction syndromes. At the time of surgery, 2% tetracaine HCl and 0.25% phenylephrine HC1 were applied topically on nasal packs. The turbinates were injected with 2-4 ml of 1% lidocaine with 1:100,000 epinephrine. The infero-lateral portions of the inferior turbinates were excised. Tissue was prepared for immunohistochemistry (see below), frozen in 2-methyl-butane for 30 s, and stored at -70°C until required, or placed in L15 transport media (Biofluids, Rockville, MD) supplemented with penicillin, streptomycin, and amphotericin before explant culture.
Extract preparation. (23) .
Paraffin sections were defatted in xylene and exposed sequentially to graded alcohols, distilled water, PBS, and PBS with 1% nonimmune goat serum (24). Sections were incubated for 18 or 44 h at 4VC with rabbit anti-GRP (1: 1,000) or anti-GRP adsorbed with 1 AM GRP. The slides were washed with PBS and exposed to 1% nonimmune goat serum in PBS for 3 min at room temperature, and then to 1:40 colloidal gold-labeled goat anti-rabbit gamma globulin (Auroprobe; Janssen Life Sciences Products, Piscataway, NJ) for 60 min at room temperature. After washing thoroughly in PBS and distilled water, silver enhancing solution (IntenSE; Janssen Life Sciences Products) was added and the development of the stain monitored by light microscopy. Slides were counterstained lightly with nuclear fast red (Sigma Chemical Co.).
Autoradiography. '25I-GRP binding was performed using methods adapted from Moran et al. (25) and Kris et al. (26) . Cryostat sections (10 Am thick) were warmed to room temperature and washed in CMRL media with aprotinin (400 kallikrein inhibitory units/ml; Sigma Chemical Co.) and 0.5% BSA for 30 min at 250C. Slides were incubated for 75 min at 4VC with 1 nM 3-'251-tyr'5-GRP (Amersham Corp.) in CMRL/aprotinin/BSA. Specific binding was determined by adding 1 nM '25I-GRP with and without 2 AM unlabeled GRP. After incubation, slides were washed four times each for 30 s with CMRL/ aprotinin/BSA at 4VC and dried with blown cold, dry air.
Nuclear track emulsion (NTB-2; Eastman Kodak Co., Rochester, NY) was melted in the dark for 4 h at 450C and then mixed with an equal volume of 1% glycerol in water. Slides were dipped in emulsion, allowed to dry in the dark (27) , and stored at -20'C. Slides were removed at intervals and developed in D-19 developer and fixer (Eastman Kodak Co.) (see reference 27) .
Nasal mucosal explant culture (14, 21, 22) . Fresh nasal mucosa was cut into 3 X 3-mm fragments. Pairs of fragments were placed on gelfoam in petri dishes, and cultured in 2 ml of CMRL 1066 media containing penicillin ( 100 pg/mIl), streptomycin (100 pug/ml), and amphotericin (0.5 ,g/ml) (Grand Island Biologicals, Grand Island, NY), and [3H]glucosamine (1 ACi/ml; New England Nuclear, Boston, MA).
The glucosamine is incorporated into newly synthesized respiratory glycoconjugates (14, 21, 22 GRP eluted only in the fraction collected between 24 and 25 min. When turbinate tissue was eluted from the HPLC column, there were many peaks eluted between 0 and 40 min. Using the RIA, GRP immunoreactive material was eluted only in the fraction collected between 24 and 25 min. All other fractions for both the standards and tissue contained no immunoreactive GRP. Therefore, human nasal turbinate GRP immunoreactive material eluted at the same time as synthetic GRP.
Indirect immunohistochemistry. GRP-immunoreactive nerves were widely distributed in human nasal mucosa. Arterioles were densely innervated by a plexus ofGRP immunoreac- (Fig. 1) . Fibers were most concentrated along the adventitial border and between vascular smooth muscle cells, although some did appear to penetrate to the intima. The walls of venous sinusoids and venules were innervated by individual fibers (Fig. 2) . Both varicose (neurosecretory) and smooth fibers were found. Individual fibers were also noted in submucosal glands between gland acini in close apposition with both the mucous and serous secretory cells (Fig. 3) . Free thelium and submucosal glands (Figs. 4, 5, and 6 ). All epithelial cells appeared to bind "25I-GRP (Figs. 4 and 6) , and there did not appear to be a preference for goblet cells or other cell types. Both mucous and serous cells of submucosal glands bound '25I-GRP (Figs. 5 and 6 ). Vessels did not exhibit 25.I-GRP binding (Figs. 5 and 6 ). The addition of excess GRP prevented binding of '25I-GRP to epithelium (Fig. 4) and submucosal glands (Fig. 5 ).
Explant culture: GRP (10 AM) significantly stimulated
[3H]glucosamine-labeled glycoconjugate release from cultured human nasal mucosal fragments. The secretory indices for GRP cultured media was 21.7±5.8% (n = 5) greater than control cultures (P < 0.02). This effect was not due to aprotinin, since aprotinin by itself did not induce glycoconjugate release (-1.8±7.3%; n = 3). Methacholine challenges (100 jAM) were included in each days' experiments as positive controls, and stimulated significant glycoconjugate release (35.7±2.7%; n = 5; P < 0.001).
Lactoferrin, a product of serous cells (20) , was released from explant submucosal gland serous cells by both 10 IAM GRP (58.1±3.5% increase above control release; n = 3; P < 0.001) and 100 IAM methacholine (76.1±24.6% increase; n = 3;P<0.05).
Discussion
These experiments are the first demonstrations that GRP can stimulate lactoferrin-and [3H]glucosamine-labeled, acid-precipitable macromolecule release from human nasal mucosal fragments. Lactoferrin is synthesized and secreted from submucosal gland serous cells (20) . 3H-Respiratory glycoconjugates (mucous) are complex mixtures of mucous glycoproteins, proteoglycans, and other glycoconjugates that are derived from epithelial goblet cells, and submucosal gland serous and mucous cells (21, 22, 29) . These results suggest that secretion from submucosal gland serous and mucous cells and potentially epithelial goblet cells was stimulated by GRP. The limited supply of human tissue did not allow full dose-response curves for GRP to be determined. However, data on secretion from cat trachea indicates that GRP is a potent stimulant of glandular secretion at doses between 10 nM and 10 IM (14, 21) .
The autoradiographic results indicate that GRP binding sites were present over submucosal glands and epithelial cells in human nasal mucosa. Immunohistochemistry confirmed the presence of GRP-immunoreactive nerves between gland acini of nasal mucosa (30, 31) . Therefore, based on three lines 4.8*bVa~J', r of evidence it can be concluded that GRP acts as a neurotransmitter that stimulates glandular secretion since: (a) GRP is present in nerve fibers in glands, (b) GRP binding sites are present in glands, and (c) when added exogenously, GRP stimulates gland secretion in vitro.
The curious pattern of innervation and GRP binding sites is of interest. GRP-immunoreactive material was found in arteriolar vessels in nasal mucosa (2, 31) The origin of GRP-containing neurons is not yet completely defined. In rat spinal sensory ganglia, GRP has been colocalized with substance P, suggesting that GRP is present in sensory neurons (7, 31, 34) . Preliminary studies in human nasal mucosa suggest that GRP, calcitonin gene related peptide, and neurokinin A have nearly identical distributions in serial immunohistochemical sections (personal observations, unpublished data). This finding suggests that GRP is localized in trigeminal nociceptive sensorimotor type C nerve fibers. Colocalization studies are in progress to verify this impression.
Should GRP be localized to sensory neurons, then sensory neuron axon reflex activation could lead to the release of GRP near submucosal glands and the epithelium. Axon reflexes have been shown to release substance P and calcitonin gene related peptide from sensory neurons in rat nasal mucosa (35, 36) , rat tracheobronchial mucosa (37) , and guinea pig heart (38) , and may contribute to the pathogenesis of asthma (39, 40) . GRP release by axon reflex mechanisms, or after capsaicin treatment, has not yet been examined. Given that GRP is a trophic hormone for respiratory tissues (10-13), it may be important to learn the mechanisms that lead to GRP release, and to further understand the effects of GRP on the mucosa.
The HPLC results indicate that GRP and human nasal mucosal GRP-immunoreactive material coelute, and that there is only a single peak of extractable GRP-immunoreactive material. This finding is at variance with an HPLC study of bronchoalveolar lavage fluid which found several "bombesinlike peptides," peptides that bound to anti-bombesin monoclonal antibodies (41) . It is possible that the concentration of bombesin-like peptides in the present study may have been too low to detect with the present assay conditions or polyclonal antiserum. However, immunohistochemical staining indicates that in the lower respiratory tract neuroendocrine cells are the prime source of bombesin-like peptides (including GRP; see reference 42). Neuroendocrine cells and specifically GRPcontaining cells were not identified in human nasal mucosa. It is possible that lower respiratory tract neuroendocrine cells contribute the bombesin-like peptides detected in bronchoalveolar lavage fluid, and that these peptides were absent from the upper respiratory tract because of the absence of neuroendocrine cells.
Based upon the original data presented here, GRP appears to be a neurotransmitter capable of inducing secretion from mucous and serous cells of the submucosal glands of human nasal mucosa. Given the dirth of vascular binding sites, GRP may have negligible effects on the tone and permeability of mucosal vessels. Thus, GRP appears be a specific regulator of glandular secretion in human nasal mucosa.
